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Simple Summary: Here, we reveal that basal turnover and autophagy-induced decay of the ubiquitin
E3 ligase TRAF6 is antagonized by IKKε-mediated phosphorylation at five serines. Phosphopro-
teomic experiments show that TRAF6 and its phosphorylation contribute to the remodeling of LPS-
and autophagyinduced signaling networks, revealing an intricate link between inflammatory and
metabolic processes that are frequently dysregulated in cancer.
Abstract: The ubiquitin E3 ligase TNF Receptor Associated Factor 6 (TRAF6) participates in a large
number of different biological processes including innate immunity, differentiation and cell survival,
raising the need to specify and shape the signaling output. Here, we identify a lipopolysaccharide
(LPS)-dependent increase in TRAF6 association with the kinase IKKε (inhibitor of NF-κB kinase
subunit ε) and IKKε-mediated TRAF6 phosphorylation at five residues. The reconstitution of TRAF6-
deficient cells, with TRAF6 mutants representing phosphorylation-defective or phospho-mimetic
TRAF6 variants, showed that the phospho-mimetic TRAF6 variant was largely protected from
basal ubiquitin/proteasome-mediated degradation, and also from autophagy-mediated decay in
autolysosomes induced by metabolic perturbation. In addition, phosphorylation of TRAF6 and its
E3 ligase function differentially shape basal and LPS-triggered signaling networks, as revealed by
phosphoproteome analysis. Changes in LPS-triggered phosphorylation networks of cells that had
experienced autophagy are partially dependent on TRAF6 and its phosphorylation status, suggesting
an involvement of this E3 ligase in the interplay between metabolic and inflammatory circuits.
Keywords: NF-κB; TRAF6; IKKε; phosphorylation; kinase activation; signaling; autophagy; LPS
1. Introduction
Transmission and amplification of immune signaling employs a cascade of enzymatic
reactions that lead to the regulated attachment of posttranslational modifications includ-
ing ubiquitination and phosphorylation [1,2]. Ubiquitin signaling employs differentially
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composed ubiquitin chains including K48-branched ubiquitin chains, which mediate the
ubiquitin/proteasome-dependent degradation of target proteins, and K63-branched polyu-
biquitin chains, which are recognized and bound by chain readers such as TAB2/TAB3
(TGF-ß activated kinase 1/MAP3K7 binding protein 2/3) [3]. Ubiquitin is attached to
substrate proteins by consecutive reactions employing E1 and E2 enzymes, with the last
step executed by an ubiquitin E3 ligase [4]. A well-studied E3 ligase with relevance to
immune cell signaling is TRAF6, which typically promotes the formation of K63-linked
polyubiquitin chains. TRAF6 contains a so-called RING (really interesting new gene) do-
main, is ubiquitously expressed and transduces signals from various immune receptors
including those of the tumor necrosis factor receptor (TNF-R) superfamily, interleukin
1 (IL-1) receptors, T-cell receptors and many toll-like receptors (TLRs) including the LPS-
responsive TLR4 [5]. Extracellular LPS leads to TLR4-dependent signaling and inducible
receptor association of TRAF6, which, in turn, allows the interaction of TRAF6 with the
E2 ubiquitin-conjugating enzyme complex (Ubc13-Uev1A) to catalyze the formation of
K63-linked polyubiquitination on itself or its substrate proteins [6]. TRAF6-mediated K63
ubiquitination of its client proteins enables interaction with the ubiquitin-binding domains
of adapter proteins such as TAB2/TAB3, which then leads to activation of downstream
kinases including TGFβ-activated kinase 1 (TAK1) [7,8]. Increased TAK1 activity triggers
the activation of proinflammatory mitogen-activated protein kinases (MAPKs) [9], thus
coupling ubiquitination to multiple downstream phosphorylation networks. TRAF6 is
controlled by several mechanisms that include inducible protein/protein interactions,
allowing its docking to surface receptors or downstream effectors. In addition, the expres-
sion levels of TRAF6 are supervised by microRNAs such as miR-146a and long noncoding
RNAs [10,11]. Furthermore, TRAF6 levels are restricted by ubiquitin/proteasome-mediated
decay or elimination in the autophagosome [12,13].
TRAF6 regulates not only immune signaling, but also further processes including
tumor cell growth [14], genome integrity [15], gene-specific mRNA decay [16] as well
as osteoclast differentiation [17]. TRAF6 also contributes to early steps in the process of
autophagy, which is induced in response to stress stimuli including growth factor deple-
tion, nutrient deprivation and infection. Autophagy serves to eliminate unwanted and
potentially harmful cytosolic material, such as protein aggregates or damaged organelles,
to provide nutrients for vital cellular functions during fasting and other forms of stress,
including infection [18,19]. TRAF6 contributes to the early steps of autophagy and pro-
motes the formation of phagophores that engulf cytosolic materials for degradation and
recycling. In this process, TRAF6 promotes phagophore formation through the K63-linked
polyubiquitination of ULK1 (Unc-51 Like Autophagy Activating Kinase 1) and BECLIN-1
(Coiled-Coil Myosin-Like BCL2-Interacting Protein) [20,21]. Phagophores further mature
to a double-membraned vesicle termed autophagosome, which then fuses with the lyso-
somal membrane to form autolysosomes, the sites where acidic hydrolases degrade the
autophagic cargo, including the TRAF6 interactor and autophagy receptor p62, also known
as Sequestosome-1 (SQSTM1) [22,23].
The process of autophagy shows many levels of cross-regulation with innate and
adaptive immunity [24]. Infection with viruses or bacteria frequently triggers autophagy,
where the invaders, such as Salmonella, are trapped within an autophagosome and targeted
to the lysosome for destruction [25]. These principal defence mechanisms may also explain
why autophagy is also induced upon stimulation of various immune receptors including
TLR4 [26,27]. Vice versa, autophagy facilitates the TLR4-induced ubiquitination of TRAF6
and activation of NF-κB, leading to increased production of cytokines [28]. The intimate
relation between autophagy and inflammation is also witnessed by the dual function of
proteins with a role in inflammatory processes and also autophagy, as exemplified by
TRAF6 and the kinases IKKε and ULK1/2 [29–31].
IKKε contributes to the type I interferon expression in response to viral infections,
as it phosphorylates and, thus, activates IRF3/7 (interferon regulatory factor 3/7) tran-
scription factors [32]. Furthermore, IKKε overexpression contributes to the development of
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breast cancer and KRAS-induced pancreas tumors [33,34]. IKKε activity is regulated by
autocatalytic phosphorylation at the activation loop, while its intracellular localization is
controlled by attachment of the small ubiquitin-like modifier (SUMO) peptide to Lys 231 in
response to DNA damage [35].
Here, we reveal an increased association between IKKε and TRAF6 in LPS-stimulated
cells and the IKKε-mediated phosphorylation of TRAF6 at five serine residues. These
phosphorylation events serve at least two functions, as they lead to the stabilization of
TRAF6 under basal conditions and in response to inducers of autophagy. In addition,
basal and stimulus-induced TRAF6 phosphorylations specify the downstream signaling
networks, as determined by phosphoproteomic analysis.
2. Materials and Methods
2.1. Cell Culture and CRISPR-Cas9-Mediated Generation of TRAF6 Knockout Cells
HeLa, HEK293 and 293 TLR4 cells were cultured in DMEM (Life Technologies, Carls-
bad, CA, USA) supplemented with 10% FCS, 100 U/mL penicillin and 100 µg/mL strep-
tomycin. A total of 293 TLR4 cells were cultured in the presence of 1 mg/mL G418. For
CRISPR-Cas9 mediated knockout of TRAF6, 1000 293 TLR4 cells per 10-cm dish were
transfected with 4 µg of the px459 vector containing a sgRNA targeting the first exon
of TRAF6. One day later, the non-transfected cells were eliminated by the addition of
puromycin (2 µg/mL) for 48 h. Single cell-derived clones were picked after approximately
one week and further analyzed for the expression of TRAF6 and Cas9.
2.2. Characterization of CRISPR-Cas9-Mediated Genomic Indel Mutations
Genomic DNA of cells deficient in TRAF6 protein expression was isolated using
the NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany). A region containing the
TRAF6 locus with the expected Indel mutation was PCR amplified using the Phusion High
Fidelity DNA polymerase (ThermoFisher Scientific, Waltham, MA, USA), 50 ng of genomic
DNA and TRAF6 intron-exon-spanning oligonucleotides. A PCR was performed in a
thermocycler with 30 amplification cycles and the purified PCR product was sequenced
using one of the PCR primers as a sequencing primer.
2.3. Induction of Autophagy
Cells that reached approximately 60% confluence were washed twice with PBS and
incubated in EBSS medium (140 mM NaCl; 1 mM CaCl2; 1 mM MgCl2; 5 mM glucose;
20 mM HEPES (pH 7.4); 1% BSA—sterile filtrated using a 0.2 µm filter) to induce autophagy,
as described previously [35]. Cells were further cultivated at 37 ◦C and 5% (v/v) CO2 for
various periods and then harvested for further analysis.
2.4. Cell Transfection and Generation of Stable Cell Lines
Cells were seeded in 10-cm dishes 24 h before transfection. A desired amount of
plasmid DNA was mixed with 200 µL of serum-free DMEM without antibiotics. Further-
more, 2 µL of linear Polyethyleneimine (PEI, 1 mg/mL H2O) per µg plasmid DNA was
mixed with serum-free DMEM without antibiotics and added to the premixed DNA to
reach a total volume of 400 µL. After an incubation of 20 min at room temperature, the
solution was transferred to the cells. The medium of those cells was exchanged with 5 mL
antibiotic-free medium with normal FCS concentration. Cells were then incubated for
4 h and the medium was replaced with complete medium. In order to generate 293 TLR4
cells that stably express the various HA-TRAF6 variants, TRAF6 knockout cells were
transfected with vectors encoding the WT and mutated TRAF6 proteins, followed by
selection with 2 µg/mL puromycin for one week. Individual cell colonies were picked
and analyzed by Western blotting for TRAF6 expression levels. Only cell clones with
comparable TRAF6 levels were used for the analysis; all key experiments were conducted
with several independent clones or cell pools in order to ensure that the effects are not due
to clonal variations.
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2.5. Lambda Protein Phosphatase Assays
To test whether the slower migration of proteins in gel electrophoresis is caused by
phosphorylation, lysates were treated with the Mn2+-dependent λ-phosphatase with activ-
ity towards all phosphorylated amino acids. For this purpose, cells were lysed under native
conditions in IGEPAL buffer lacking phosphatase inhibitors and cleared supernatants were
mixed with 400 units of λ-phosphatase, supplemented with 2 mM MnCl2 and incubated at
30 ◦C for 20 min. Samples were then mixed with 5 × SDS sample buffer and heated for
4 min at 95 ◦C for further Western blot analysis.
2.6. Denaturing Lysis and Enrichment of His-Tagged Proteins on Ni-NTA Columns
His6-Ubiquitin-modified proteins expressed in eukaryotic cells were enriched after
lysis under denaturing conditions using Ni-NTA agarose beads (Qiagen, Hilden, Germany).
The cells were collected by centrifugation and 1/10 of the cells were used as input control
and lysed using 1 × SDS sample buffer. The remaining cells were lysed in 650 µL Gu-HCl
lysis buffer (6 M Guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM Tris-Base, 10 mM
Imidazole, 1 mM ß-Mercaptoethanol pH = 8.0). The DNA was sheared by sonification and
lysates were cleared by centrifugation (10 min, 16,000× g). The supernatant was mixed
with 60 µL of equilibrated Ni-NTA agarose, followed by incubation for at least 4 h at room
temperature under agitation. Subsequently, the beads were serially washed in different
Urea wash buffers, as described previously [36], and the bound proteins were eluted by
boiling the beads for 5 min in 50 µL 2.5 × SDS sample buffer containing 200 mM imidazole.
The purified His6-Ubiquitin-modified proteins were further analyzed by immunoblotting.
2.7. Native Cell Lysis and Co-Immunoprecipitation
Cells were washed first with cold 1 × PBS, harvested by scraping in 1 mL of PBS
and then transferred to reaction tubes. After centrifugation (300× g, 5 min), the cell pellet
was resuspended in IGEPAL lysis buffer (20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1%
(v/v) IGEPAL CA-630, freshly added: 20 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 4 µg/mL
aprotinin, 4 µg/mL leupeptin, 0.5 mM PMSF) and incubated for 20 min on ice. Cell
debris was cleared by centrifugation (16,000× g, 10 min); the supernatants were transferred
to a new tube and either used for co-immunoprecipitation experiments or mixed with
5 × SDS sample buffer, boiled at 95 ◦C for 5 min and analyzed by Western blotting. Co-
immunoprecipitation was performed by pre-clearing of the lysates by the addition of
15 µL of A/G-agarose bead slurry and incubation for 1 h at 4 ◦C under agitation. After
centrifugation (5 min, 2000× g), the cleared lysate was transferred to a fresh tube. In total,
10% of lysate was used for the input control and the rest was adjusted to a volume of
500 µL with IGEPAL lysis buffer. Quantities of 1 µg of the immunoprecipitating antibody
or control IgG antibody and 25 µL of protein A/G agarose were added. The samples were
incubated for 4 h at 4 ◦C on a rotating spinning wheel. The beads were washed five times
with 1 mL of cold IGEPAL buffer by inverting the tube, followed by centrifugation (1 min,
2000× g). Proteins were eluted from the beads with 1.5 × SDS sample buffer and analyzed
by Western blotting as described previously [31].
2.8. Mass Spectrometry for Detection of TRAF6 Phosphorylation Sites
293T cells were transfected to express Flag-tagged IKKε and Flag-tagged TRAF6.
The next day, cells were lysed in IGEPAL lysis buffer containing phosphatase inhibitors,
followed by immunoprecipitation of TRAF6 and IKKε using anti-FLAG antibodies. The
proteins were eluted by incubation with SDS sample buffer and subjected to SDS-PAGE.
Gels were stained by Coomassie Brilliant-Blue G-250 and bands corresponding to TRAF6
were excised and subjected to proteomic analysis.
2.9. Phospho-Proteomic Analysis of TRAF6-Mediated Signaling Pathways
HEK293 TLR4 cells stably expressing TRAF6 WT and its mutants were grown to 70%
confluence, followed by treatment and LPS stimulation as specified in the figure legends.
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After treatment, cells were washed with cold PBS and lysed in Urea lysis buffer (20 mM
HEPES (pH 8.0), 9.0 M urea, 1 mM activated Na3VO4, 2.5 mM Na4P2O7, 1 mM ß-glycerol-
phosphate). Samples were sonicated and centrifuged for 20 min at 4 ◦C at 16,100× g.
The supernatants were collected, and the protein concentration was determined using a
Bradford assay. An aliquot was used for control Western blots, ensuring the successful
cell treatment, while the remaining material was used for mass spectrometry. Samples
containing 2 mg total protein each dissolved in 8 M urea were reduced with 5 mM TCEP for
1 h at 37 ◦C/1000 rpm, and carbamidomethylated by incubating the samples with 10 mM
iodoacetamide at 500 rpm for 30 min at room temperature in the dark. Subsequently,
N-Acetyl-cystein was added to a final concentration of 12.5 mM. Samples were diluted to
6 M urea through the addition of 0.1 M NH4HCO3. LysC was added at a concentration of
1:200 in relation to the total protein content (w/w) and samples were incubated for 3–4 h at
37 ◦C. Prior to the addition of sequencing grade trypsin (1:50 (w/w)), samples were further
diluted to a urea concentration of 1.6 M using 0.1 M NH4HCO3. After incubating samples
overnight at 37 ◦C, the samples were acidified using TFA and peptides were desalted and
concentrated using Chromabond C18WP spin columns (Macherey-Nagel, Part No. 730522).
Finally, peptides were dissolved in 25 µL of water with 5% acetonitrile and 0.1% formic acid.
Phosphopeptide enrichment was performed with MagReSyn Ti-IMAC magnetic beads
(ReSyn Biosciences, Edenvale, South Africa) according to the manufacturer’s protocols.
Finally, samples were dissolved 25 µL 5% MeCN/0.1% TFA. The mass spectrometric
analysis of the samples was performed using an Orbitrap Velos Pro mass spectrometer
(ThermoFisher Scientific, Waltham, MA, USA). An Ultimate nanoRSLC-HPLC system
(Dionex, Sunnyvale, CA, USA), equipped with a custom end-fritted 50 cm × 75 µm C18 RP
column filled with 2.4 µm beads, was connected online to the mass spectrometer through a
Proxeon nanospray source. Then, 6 µL of the tryptic digest were injected onto a 300 µm ID
× 1 cm C18 PepMap pre-concentration column (Thermo Scientific). Automated trapping
and desalting of the sample were performed at a flowrate of 6 µL/min using water/0.05%
formic acid as solvent. Separation of the tryptic peptides was achieved with the following
gradient of water/0.05% formic acid (solvent A) and 80% acetonitrile/0.045% formic acid
(solvent B) at a flow rate of 300 nL/min: holding 4% B for five minutes, followed by a linear
gradient to 45% B within 30 min and linear increase to 95% solvent B for an additional 5 min.
The column was connected to a stainless steel nanoemitter (Proxeon, Odense, Denmark)
and the eluent was sprayed directly towards the heated capillary of the mass spectrometer
using a potential of 2300 V. A survey scan with a resolution of 60,000 within the Orbitrap
mass analyzer was combined with twenty data-dependent MS/MS scans with dynamic
exclusion for 30 s using CID with the linear ion-trap and multistage activation enabled. For
better data reliability, a technical replicate was measured for all samples. Data analysis was
performed using Proteome Discoverer 2.2 (Thermo Scientific) with the SEQUEST search
engine (Accessed on 18 August 2020) or MaxQuant (Version 1.5.7.4) with the Andromeda
(Accessed on 18 August 2020) search engine.
2.10. LC-MS/MS Analysis
For the identification of TRAF6 phosphorylation sites, SDS-PAGE gel bands corre-
sponding to TRAF6 in the absence or presence of IKKε have been excised and processed by
tryptic in-gel proteolysis following standard protocols [37]. Extracted and dried peptides
were re-dissolved in 0.5% TFA and subjected to LC-MSMS analysis on a nanoflow HPLC
system (Ultimate 3000 RSLC; Thermo Fisher) coupled to an Orbitrap Velos (Thermo Fisher)
tandem mass spectrometer using 120 min gradients for the C-18 reverse chromatography
and a TOP10 method combined with CID fractionation for MSMS. In addition, for evi-
dence of the exact phospho-site, multi-stage activation has been used. For database search,
tandem mass spectra were extracted by MSConvert (version year 2010). Charge state
deconvolution and deisotoping were not performed. All MS/MS samples were analyzed
using Mascot (Matrix Science, version 2.3). Mascot was set up to search the SwissProt
database (selected for Homo sapiens, 2010_12, 20,259 entries, accessed on 30 October 2010)
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assuming the digestion enzyme trypsin. Mascot was searched with a fragment ion mass
tolerance of 0.60 Da and a parent ion tolerance of 10.0 PPM. Carbamidomethyl of cysteine
was specified in Mascot as a fixed modification. Deamidation of asparagine and glutamine,
and oxidation of methionine and phospho-serine/threonine/tyrosine were specified in
Mascot as variable modifications. The search engine results/spectra were analyzed and
visualized by Scaffold (Proteome Software, version 3_00_8).
2.11. Statistical Rationale and Bioinformatic Analysis
The protein signals from Western blots were detected using the ChemiDocTM XRS+
System (Bio-Rad Laboratories, Hercules, CA, USA) and further processed using Image Lab
Software. For the data shown in Figures 6–8 and Figure S6, raw data from 82 LC-MS/MS
runs (representing three independent experiments and two technical replicates per sample,
except for samples 322 (P-def + EBSS + LPS) and 332 (P-mim. untreated), which had only
one sample measured (with no technical replicate)) were mapped to the Homo sapiens
proteome (uniprot ID UP000005640). All data sets were processed by MaxQuant (version
1.6.14.0 [38], with the match between runs option enabled), resulting in the identification
of 17,220 human protein IDs that corresponded to phosphorylated peptides. The log2-
transformed phosphopeptide intensities were width normalized and log2 transformed
with Perseus 1.6.14.0 [39]. IDs assigned to contaminants and reverse sequences were
omitted. The 3 × 2 replicates from each condition were assigned to one analysis group
and, for further calculations and for comparisons between treatment groups by two sample
Student’s T-tests, 2835 phosphopeptides with at least 5 intensity values per peptide in at
least one group were selected. From this group, differentially expressed phosphopeptides
were identified from log2 transformed normalized protein intensity values by T-test analysis
based on a p-value ≤ −log10 of 1.3. In addition, phosphopeptides only found in one out of
two pairwise comparisons were considered as regulated and added to the total number of
differentially regulated phosphopeptides per condition. Subsequent filtering steps were
performed in Excel 2016 according to criteria described in the figure legends. Graphical
representations were generated with GrapPad Prism 8.4.3. Venn diagrams were created
with tools provided at http://bioinformatics.psb.ugent.be/webtools/Venn/, accessed on
18 May 2021. Overrepresentation analyses of gene sets were conducted using majority
protein IDs or gene IDs that corresponded to differentially enriched phosphopeptides
using Metascape software (https://metascape.org/, accessed on 18 May 2021) with the
express settings [40]. Clustered enrichment maps show the top 20 pathways and the
enrichment p-values.
2.12. Antibodies, Plasmids and Reagents
This information is given in Table S1.
3. Results
3.1. IKKε Shows LPS-Triggered Interaction with TRAF6 and Phosphorylates TRAF6 at Five
Different Serines
We had previously found the regulation of IKKε by SUMOylation [41] and were
interested in learning more about the regulation of this kinase. During our experiments, we
made the serendipitous observation that IKKε and TRAF6 showed a weak interaction in
untreated cells (Figure 1A), which is consistent with the published literature [42]. However,
the interaction between IKKε and TRAF6 was significantly enhanced after LPS stimula-
tion, as observed for epitope-tagged proteins (Figure 1A) and the endogenous proteins
(Figure 1B). In the course of these experiments, we noted that co-expression of IKKε led to
the occurrence of a slower migrating TRAF6 band in the presence of co-expressed IKKε, but
not in cells expressing the kinase inactive IKKε-K38A variant (Figure 1C). To test whether
this upshift is due to TRAF6 phosphorylation, HEK293 cells transfected to express Flag-
TRAF6 alone or together with Flag-IKKεwere lysed under native conditions and incubated
with λ-phosphatase. Immunoblotting showed that treatment with λ-phosphatase reverted
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the IKKε-triggered upshift, suggesting that the slower migrating band corresponds to
phosphorylated TRAF6 (Figure 1D).
Figure 1. LPS-inducible interaction between IKKε and TRAF6. (A) HEK293 cells stably expressing
TLR4 (293 TLR4) were transfected to express Myc-IKKε either alone or along with Flag-TRAF6.
Cells were treated with LPS (2 µg/mL) for the indicated periods and lysed under native conditions.
One aliquot of the extract was used for the input control; the remaining material was used for
immunoprecipitation with anti-Flag antibodies. After elution of bound proteins, coprecipitated IKKε
was visualized by Western blotting with anti-Myc antibodies. (B) HEK293 TLR4 cells were stimulated
with LPS, as shown, and one aliquot of each cell extract was used for co-immunoprecipitation using
anti-IKKε antibodies. (C) HEK 293 cells were transfected to express HA-TRAF6 alone or together with
Flag-IKKε or Flag-IKKε-K38A, as shown. Cells were lysed under denaturing conditions, TRAF6 and
the slower migrating form were detected by Western blotting using anti-HA antibodies. (D) HEK293
cells transfected to express Flag-TRAF6, alone or together with Flag-IKKε, were lysed under native
conditions and incubated with λ-phosphatase for 20 min. TRAF6 and its phosphorylated form were
detected by Western blotting with anti-TRAF6 antibodies.
To identify the IKKε-mediated phosphorylation sites, a mass spectrometry approach
was used. Flag-tagged TRAF6 was expressed either alone or together with Flag-IKKε in
HEK293T cells, followed by immunoprecipitation of both Flag-tagged proteins and mass
spectrometry (Figure 2A and Figure S1). These experiments allowed the identification of
IKKε-dependent phosphorylation at five serines at positions 129, 188, 268, 279 and 324,
as schematically shown in Figure 2B. Constitutive phosphorylation at Ser 188 has already
been identified [43], while all other phosphorylation sites have not yet been reported.
The sequences surrounding the modification sites match well to a IKKε consensus motif
(Figure 2C). Visualization of the phosphorylation sites on the TRAF6 part with available
structural information shows the positions of Ser 129 and Ser 188 on the N-terminal
dimerization and Ubc13 interaction domain (Figure 2D). The position of Ser 129 at the end
of the α-2 Helix is located within a region that has been shown to interact with the donor
ubiquitin [44].
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Figure 2. Mapping of IKKε-mediated TRAF6 phosphorylation sites. (A) HEK293T cells were used to express Flag-
tagged forms of IKKε and TRAF6, as shown. Native extracts were produced and Flag-tagged proteins were purified
by immunoprecipitation using anti Flag antibodies. One aliquot of the immunoprecipitated material was analyzed by
SDS-PAGE and Coomassie brilliant blue (CBB) staining; the positions of molecular weight markers are indicated. The
remaining material was used for SDS-PAGE, followed by excision of TRAF6 and mass spectrometric identification of TRAF6
phosphorylation sites. (B) Domain organization of TRAF6: RING = Really Interesting New Gene, Zn finger = zinc finger,
CC = coiled coil region, TRAF-C = conserved C-terminal TRAF domain. The position of the phosphorylated serines identified
via mass spectrometry are shown, the asterisk (*) indicates a known phosphorylation site, and the underlined residues are
conserved in mouse TRAF6. (C) The sequences around the identified modification sites are listed and compared to the
IKKε consensus phosphorylation sequence logo (deduced from 106 different input sequences) from the PhosphoSitePlus®
database. (D) The positions of TRAF6 phosphorylation sites on regions with available structural information are shown.
The crystal structure showing the dimeric N-terminal domains of TRAF6 representing amino acids 54–210 (PDB code:
3HCS) was used to highlight the positions of two phosphorylated amino acids in red using Pymol.
3.2. TRAF6 Phosphorylation Counteracts Constitutive and LPS-Inducible Decay
To address the functional relevance of these phosphorylation events in vivo, we aimed
to reconstitute the expression of wildtype (WT) and mutated forms of TRAF6 in TRAF6-
deficient cells. To do so, TRAF6 was knocked-out using the CRISPR-Cas9 system in 293
TLR4 cells (Figure S2A,B). These TRAF6-deficient cells were used to stably reconstitute
the expression of tandem HA-tagged forms of various TRAF6 variants: the WT form,
phosphorylation-deficient TRAF6 where all the phosphorylated amino acids identified in
this study were mutated to alanine (TRAF6 P-def), phospho-mimetic TRAF6 with Ser to
Glu mutations in all phosphorylation sites identified here (TRAF6 P-mim), and, as a further
control, the catalytically inactive TRAF6 C70A zinc finger mutant. Cells expressing similar
levels of these TRAF6 variants comparable to the level of endogenous TRAF6 were gener-
ated (Figure 3A) and analyzed further. As TRAF6 stability is regulated in response to many
external cues including virus infections, micro RNAs and inflammation [11–13], it was inter-
esting to compare the protein stabilities of the different TRAF6 forms. Cells were incubated
for different periods with the protein synthesis inhibitor Anisomycin and protein extracts
were prepared to determine TRAF6 protein amounts. While the expression of TRAF6
WT and TRAF6 P-def was significantly reduced 8 h after translation inhibition, marked
differences were observed for TRAF6 C70A and TRAF6 P-mim (Figure 3B). While TRAF6
C70A was highly instable and almost undetectable after 8 h of Anisomycin treatment, the
TRAF6 P-mim mutant showed only very minor protein decay. TRAF6 degradation did not
occur in the presence of the proteasome inhibitor MG132 (Figure 3B), consistent with the
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notion that basal TRAF6 decay is mediated by the ubiquitin/proteasome system. To test
the impact of TRAF6 phosphorylation on its basal ubiquitination, the different cell lines
expressing TRAF6 variants were transfected to express His6-tagged ubiquitin, followed by
the enrichment of ubiquitinated proteins on Ni-NTA columns. This experiment revealed
significantly impaired basal autoubiquitination of TRAF6 P-mim (Figure 3C).
Figure 3. Generation and characterization of cell lines expressing mutant TRAF6. (A) TRAF6-deficient cells were transfected
to stably express the indicated TRAF proteins that were C-terminally fused to a tandem HA-tag; the clone numbers
are indicated on the top. (B) The indicated cell lines were incubated with Anisomycin (7.5 µg/mL), either alone or in
combination with MG132 (20 µM), for the indicated periods. Cell extracts were prepared and analyzed for expression of the
indicated proteins by Western blotting. (C) The indicated cell lines were used to express His-tagged ubiquitin, as shown.
Cells were lysed under denaturing conditions, one aliquot was used for the input sample, while the remaining material was
used to enrich His6-ubiquitinated proteins on Ni-NTA beads. The eluted samples were analyzed by Western blotting to
detect TRAF6 ubiquitination using anti-TRAF6 antibodies.
It was then interesting to investigate whether TRAF6 phosphorylation also affects its
stability in response to cell stimulation. To address this question, cells were stimulated
for different periods with LPS, in the absence or presence of Anisomycin, to prevent re-
synthesis of the eliminated protein and to enable proper detection of changes in TRAF6
levels. Western blot experiments revealed that LPS alone did not result in reduced TRAF6
levels (most likely due to the re-synthesis of TRAF6, as the effects of LPS were only visible
in the presence of Anisomycin), and LPS-triggered TRAF6 decay was decreased in TRAF6
P-mim cells (Figure 4A). A quantitative analysis of basal and LPS-induced TRAF6 decay,
showing the stabilization of TRAF6 P-mim and also the destabilization of TRAF6 C70A, is
displayed in Figure 4B.
3.3. TRAF6 Phosphorylation Counteracts TRAF6 Elimination by Autophagy
As TRAF6 is involved in the regulation of diverse biological processes, it was interest-
ing to study whether phosphorylation-dependent control of TRAF6 stability also occurs in
response to further cues. To investigate the impact of autophagy on TRAF6, cells expressing
the different variants of this ubiquitin E3 ligase were incubated in EBSS (Earle’s balanced
salts solution) medium, which represents poor nutrient conditions [45]. This treatment
caused the induction of autophagy (indicated by p62 degradation) and led to reduced levels
of TRAF6 WT in 293 TLR4 cells (Figure 5A). Similar results were obtained in further cell
systems such as HeLa cells (Figure S3). While the amounts of TRAF6 WT and TRAF6 P-def
were clearly diminished 6 h post induction of autophagy, the phospho-mimetic TRAF6
mutant remained largely stable under these conditions (Figure 5A). Interestingly, the IKKε
expression level did not change upon starvation. This result suggests that TRAF6 phospho-
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rylation blocks TRAF6 decay also in autophagic cells. In this setting, TRAF6 degradation
proceeds by autophagy and, accordingly, it was largely abrogated by the lysosomal inhibitor
NH4Cl (Figure 5B). In contrast, it was only incompletely rescued by a proteasome inhibitor
(Figure S4), most probably due to the effects on ongoing basal degradation. Interestingly,
the TRAF6 C70A mutant that displayed an increased decay in LPS/Anisomycin-treated
cells (see Figure 4A,B) was stabilized in cells undergoing autophagy (Figure 5A), suggesting
the occurrence of different degradation pathways. As autophagy can also be induced by
inflammatory signals such as LPS [21,46], we investigated whether LPS and EBSS cooperate
in TRAF6 degradation during autophagy. The simultaneous induction of autophagy by
LPS together with EBSS resulted in an increased TRAF6 decay when compared to EBSS
treatment alone (Figure 5C). In addition, in this experimental setting, the phospho-mimetic
TRAF6 variant and the TRAF6 C70A mutant showed increased stability. In EBSS-treated
cells, the decay of TRAF6 occurred significantly later when compared to p62, suggesting
that TRAF6 is eliminated rather late during autophagy.
Figure 4. Analysis of LPS/Anisomycin-dependent TRAF6 degradation. (A) The indicated cell lines were incubated with
Anisomycin either alone or in combination with LPS for the indicated periods. Cell extracts were prepared and analyzed for
expression of the proteins, as shown. (B) Triplicates of the Western blots displayed in (A) were used for protein quantification
using the ChemiDoc Imaging System. Relative protein amounts were normalized to Actin levels, and TRAF6 expression in
untreated cells was arbitrarily set to 100%; the error bars show standard deviations.
3.4. The E3 Ligase Function of TRAF6 and Its Phosphorylation Differentially Shape LPS-Triggered
Signaling Networks
Although lacking any intrinsic kinase activity, the TRAF6 protein is necessary to trigger
LPS-inducible activation of downstream protein kinases including JNK (c-Jun N-terminal
kinase) and IκB kinases (IKKs) (Figure 6A). Given the relevance of TRAF6 as a central
mediator of immunity and cell homeostasis [17,47–49], we were interested in analyzing the
impact of TRAF6 phosphorylation on downstream signaling networks. TRAF6-dependent
signaling causes activation of protein kinase networks that were interrogated by phospho-
proteomic analyses to address the following questions: (I) What is the relative contribution
of TRAF6 phosphorylation and its E3 ligase function to the regulation of basal and stimulus-
induced phosphorylation networks? (II) What is the impact of autophagy on the ability of
TRAF6 and its phospho-mutants to mediate subsequent LPS-regulated phosphorylation
changes? To address these questions, cells expressing TRAF6, and mutants thereof, were
exposed to nutrient poor medium and/or LPS in various combinations, as schematically
shown in Figure 6B. Cell extracts from three biological replicates were digested with trypsin
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and phosphorylated peptides were enriched via immobilized metal affinity chromatog-
raphy (IMAC) columns, followed by MS/MS analysis in two technical replicates. This
allowed the identification of 2835 peptides with at least five intensity values per peptide
in at least one group. A display of mean normalized phospho-peptide intensities ensured
the comparability of data sets (Figure 6B and Figure S5). For the subsequent analyses,
we display results from phosphopeptides where a p-value could be calculated, but also
from samples without a p-value, due to the fact that a phosphorylation was not occur-
ring/detected under at least one condition, such as in untreated cells. All data from the
phosphoproteomic analysis are displayed in Table S2. In cells expressing WT TRAF6,
the treatment with LPS caused increased phosphorylation of 142 peptides and decreased
phosphorylation of 198 phosphopeptides. The dynamic range was fully maintained in
cells expressing TRAF6 C70A (Figure 6C). However, a comparison of the phosphopeptides
revealed limited overlap between phosphopeptides co-regulated by TRAF6 and its E3
ligase deficient mutant (Figure 6D).
Figure 5. Analysis of TRAF6 degradation during autophagy. (A) The indicated cell lines were incubated in autophagy-
inducing EBSS medium for the indicated periods. Cell extracts were analyzed by immunoblotting to visualize the decay
of TRAF6 and of p62, a well-known substrate of the autophagosome. (B) Cells were incubated in the absence or presence
of EBSS medium and/or NH4Cl (10–50 mM), as shown. The effects on the amount of TRAF6 and the other indicated
proteins were measured by immunoblotting. (C) The experiment was conducted as in (B) with the exception that cells were
incubated with EBSS and/or LPS.
These results suggest that (I) the ubiquitin conjugating function of TRAF6 is critically
involved in the shaping of LPS-induced phosphorylation networks, and (II) the signaling
function of TRAF6 does not entirely rely on its E3 ligase activity, likely by functioning as
a scaffold that allows dimerization with further TRAFs and signaling proteins. The com-
parative analysis of TRAF6 phosphorylation on its ability to trigger downstream signaling
networks revealed an intact ability of the TRAF6 phospho-mutants to trigger LPS-induced
phosphorylations, while the number of downregulated phosphopeptides was markedly re-
duced (Figure 7A). In addition, the phosphorylation-defective or phospho-mimetic TRAF6
forms showed strong changes between the phosphopeptide patterns in untreated and
LPS-stimulated cells, when compared to the TRAF6 WT protein (Figure 7B). Given that the
E3 ligase function of TRAF6 and its phosphorylation shape differential signaling outputs, it
was interesting to analyze those further. The three TRAF6 mutants showed only a limited
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overlap in substrates (Figure 7C), suggesting that phosphorylation critically defines the
signaling output. Although TRAF6 modification drastically altered the regulated phospho-
peptides, mapping of the differentially regulated phosphopeptides to GO/KEGG pathways
using Metascape software revealed that the phosphorylation targets still fall in largely
similar functional categories covering processes such as regulation of mRNA processing,
cell cycle and the stress response (Figure 7D). Cells expressing the TRAF6 phospho-mutants
had lost dynamic phosphorylation of proteins involved in some processes including the
regulation of apoptosis, DNA replication and gene expression (Figure 7D and Figure S6),
suggesting that modification of TRAF6 reshapes the signaling output.
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Figure 6. Analysis of LPS-induced TRAF6-dependent phosphorylation networks. (A) The indicated cells, either expressing
endogenous TRAF6, deleted in TRAF6 or reconstituted to express TRAF6 in fusion with a C-terminal tandem HA tag, were
stimulated for various time periods with LPS. Cell extracts were analyzed for basal and LPS-inducible phosphorylation
of signaling proteins with specific antibodies, as shown. Note that the tandem HA tag increases the molecular weight of
TRAF6. (B) Schematic display of the experimental setup and cell treatment. EBSS treatment was always performed for 5 h
and LPS treatment for 30 min. Cells experiencing consecutive EBSS and LPS treatment were allowed to recover for 30 min
followi g st rvation. The subsequent LC-MS/MS workflow is indicated. The Violin pl ts show total numbers and mea
normalized pho phopeptide intensities under the various conditions. (C) The top show the experimental design; the lower
part shows the number of phosphopeptide th t were increased or decr ase after LPS stimulation in TRAF6 WT or TRAF6
C70A expressing cells. We separately show regulated peptides where a p-value could not be calculated due to the fact that
phosphorylation was not occurring/detected in at least one of the samples. (D) The Venn diagram shows a comparison
of phosphopeptides (up- or downregulation) determined in unstimulated or LPS-treated cells expressing TRAF6 WT or
TRAF6 C70A.
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Figure 7. The impact of TRAF6 phosphorylation on LPS-triggered phosphorylation networks. (A) The top shows the
experimental design; the lower part shows the number of phosphopeptides that were increased or decreased after LPS
stimulation in the cells expressing TRAF6 and its phospho-mutants. (B) The Venn diagram shows a comparison of
phosphopeptides (up or downregulation) determined the in unstimulated or LPS-treated cells as indicated. (C) Venn
diagram comparing the dynamically regulated phosphopeptides in cells expressing TRAF6 C70A or the indicated TRAF6
phosphorylation site mutants. (D). Protein IDs mapping to the unique groups of deregulated phosphopeptides shown in
the Venn diagram of (C) were further used to perform an overrepresentation (ORA) analysis using Metascape. The enriched
pathway terms are indicated; the grey fields visualize lack of enrichment.
3.5. TRAF6-Dependent Signaling Networks Are Regulated by Nutrient Availability
To test the impact of autophagy and basal TRAF6 phosphorylation on signaling cas-
cades, cells expressing TRAF6 WT, TRAF6 P-def or TRAF6 P-mim were left untreated or
exposed for 5 h to EBSS medium, followed by the analysis of the phosphorylation status. In
cells expressing TRAF6 WT, the induction of autophagy resulted in dynamically regulated
changes in the phosphoproteome with a bias towards reduced phosphorylation (Figure 8A).
In cells expressing TRAF6 phospho-mutants, the dynamic range of autophagy-regulated
phosphopeptides was diminished (Figure 8A). We then investigated the functional con-
sequences of autophagy on the ability of cells to trigger a subsequent signaling response
to LPS. To address this question, cells were starved for 5 h in EBSS medium, followed
by the addition of DMEM (30 min) to allow cell recovery, and LPS stimulation for an-
other 30 min. A phosphoproteomic analysis showed an increased downregulation of
LPS-regulated phosphorylations in cells expressing a phosphorylation-deficient TRAF6
mutant (Figure 8B). A comparative analysis of LPS-regulated phosphopeptides showed
that prior induction of autophagy led to a reduced number of LPS-regulated phosphoryla-
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tions. There was a core of 141 phosphopeptides that were dynamically regulated under
all conditions in response to LPS treatment, here referred to as canonical phosphopep-
tides (Figure 8C). In addition, variable numbers of LPS-regulated phosphopeptides only
occurred in a manner that was dependent on TRAF6 phosphorylation, or in cells that
had experienced autophagy (Figure 8C). Mapping of the phosphopeptides to GO/KEGG
pathways showed that the diversity and differences at the level of phosphopeptides is
only partially reflected at the level of biological processes, which show significant overlap
(Figure 8D). The previous experience of autophagy changed the phosphorylation patterns,
leading to an underrepresentation of proteins involved in chromatin modification, DNA
repair and stress granule assembly, while enabling phosphorylation of proteins involved
in cytoskeleton organization. The EBSS/LPS-mediated processes were further affected by
TRAF6 phosphorylation, leading to the underrepresentation of proteins that regulate RNA
splicing, and reorganization of the cytoskeleton and the cell cycle (Figure 8D).
Figure 8. The impact of autophagy and TRAF6 phosphorylation on LPS-triggered phosphorylation networks. (A) The top
shows the experimental design, the lower part shows the number of phosphopeptides that were increased or decreased
after EBSS treatment in the cells expressing TRAF6 and its phospho-mutants. (B) Cells were exposed to EBSS, followed by
re-addition of complete medium. Then, cells remained untreated (controls) or were stimulated with LPS, as shown, followed
by phosphoproteomic analysis. The number of regulated phosphopeptides in the various cell lines is shown. (C) Venn
diagram comparing the dynamically regulated phosphopeptides from LPS-induced cells in dependence on starvation
and TRAF6 phosphorylation as shown. The white boxes mark commonly regulated phosphopetides that are defined as
canonical LPS-regulated. (D) Protein IDs that map to the canonical group of LPS-regulated phophopeptides as well as to
the unique phosphopeptides shown in the Venn of (C) were subjected to ORA analysis.
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4. Discussion
The TRAF6 protein has been implicated in a large number of different biological
processes, ranging from differentiation to inflammatory signaling and autophagy. This
raises the need to specify the signaling output networks to suit the specific requirements
of the biological response. This study shows that TRAF6 phosphorylation (I) affects the
control of basal and autophagy-regulated TRAF6 abundance and (II) has a profound impact
on downstream signaling networks, as schematically visualized in Figure 9.
Figure 9. Schematic model summarizing the mechanisms and functions of TRAF6 phosphorylation
for protein stability and downstream signaling networks.
Some LPS-induced signaling pathways such as processing and localization of RNA
are not affected by TRAF6 phosphorylation, while other pathways including cytoskeletal
organization as well as cell division and proliferation are shaped by TRAF6 modifica-
tion (Supplementary Figure S6). All of these distinct downstream pathways can be as-
sociated with immune signaling, which goes along with immune cell proliferation and
cytoskeletal reorganization [50], but may also affect further unrelated TRAF6-mediated
biological processes.
The regulation of TRAF6 stability has been observed in a number of different set-
tings [11–13]. Infection of cells with a number of various viruses including Hepatitis C virus
(HCV), Coronaviruses (CoV) and the bovine herpes virus (BHV-1) leads to the degradation
of TRAF6 to enable escape from host cell immune signaling by different decay pathways.
The CoV-encoded protein ORF-9b instructs the E3 ligase AIP4 to trigger TRAF6 degradation
by promoting K48-linked polyubiquitination and proteasomal degradation [51]. The same
proteolytic pathway is employed by the BHV-1-encoded infected cell protein 0 (BICP0),
which directly binds to TRAF6 in order to facilitate its ubiquitin/proteasome-mediated
elimination [52]. In contrast, HCV infection leads to p62-dependent depletion of TRAF6 in
autophagosomes [12]. In addition, dysregulated expression of cellular proteins, as it occurs
in cancer, can lead to TRAF6 degradation. High expression levels of the kinases DRAK1
(death-associated protein kinase-related apoptosis-inducing kinase 1) or c-Cbl (Casitas
B-lineage Lymphoma) lead to ubiquitin/proteasome-mediated TRAF6 decay [14,53].
This study shows that TRAF6 phosphorylation controls two distinct degradation path-
ways: (I) Basal and constitutive TRAF6 turnover occurs through the ubiquitin/proteasome
system, and increased stability of phosphorylated TRAF6 could potentially be attributed to
phosphorylation of Ser 129. This site is located in a region that mediates trans-interactions
with the donor ubiquitin (see also Figure 2D). As it was shown that mutation of TRAF6 Ser
129 to Ala slightly decreased TRAF6 autoubiquitination [44], it is conceivable that the addi-
tion of a bulky and negatively charged phosphate group will have a more profound impact
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on TRAF6 autoubiquitination. Accordingly, we have observed reduced auto-ubiquitination
of TRAF6 P-mim (see Figure 3C, but it remains to be seen whether the other phosphoryla-
tion sites also contribute to TRAF6 stabilization. (II) The second TRAF6 decay pathway
occurs in response to metabolic perturbation and proceeds by autophagy. This study shows
that autophagy-mediated TRAF6 elimination occurs rather late, as revealed by comparison
to the decay kinetics of the early autophagy substrate p62. While TRAF6 participates in
the induction phase of autophagy [20,21,54], its elimination in the late phase contributes
to a reprogramming of inflammatory phosphorylation networks. We speculate that this
might result in diminished inflammation, and accordingly anti-inflammatory effects of
autophagy have also been suggested by the analysis of mice lacking the autophagy gene
Atg16L1 (autophagy-related 16-like 1). These knockout animals have an increased host
defense and are resistant to intestinal disease induced by the model bacterial pathogen
Citrobacter rodentium [55]. The elevated immune response after elimination of autophagy
genes is also seen in response to virus infections. Here, ablation of the Epg5 (ectopic
P-granules autophagy protein 5 homolog) gene leads to increased baseline inflammation
and resistance to lethal influenza virus infection [56].
We currently have no mechanistic explanation for the phosphorylation-dependent
protection of TRAF6 from autophagic decay. Given the reduced ubiquitination of TRAF6
P-mim, one possible mechanism would involve the TRAF6 interactor p62, which serves as
a receptor targeting ubiquitinated proteins to phagophores for degradation [57]. Alterna-
tively, the addition of phosphate groups could affect protein/protein interactions or the
conformation of TRAF6.
The function of TRAF6 phosphorylation in the specification of signaling output pro-
grams will not only be due to different expression levels, as discussed above, but probably
also to effects on the strength and duration of protein/protein interactions, protein localiza-
tion and enzymatic activities [58]. These mechanisms can create differentially composed
multi-protein complexes that shape distinct signaling outputs. These interaction partners
could be hetero-dimerization partners such as TRAF2, TRAF3 and TRAF5 [59], but also
numerous other cellular proteins that bind in a constitutive or signal-regulated manner, as
discovered here for IKKε. Basal or signal-induced TRAF6 phosphorylation can potentially
affect the composition of ubiquitin chains on its target proteins, as TRAF6 may also form
atypical ubiquitin linkages in addition to the known K63-branched chains [60]. Potential
TRAF6-dependent downstream kinases feeding into these phosphorylation networks in-
clude TAK1 [61], the LPS-inducible TRAF6 interactor TBK1 [62], and probably also further
kinases including IKKε. This might involve TRAF6-mediated ubiquitination of IKKε,
which occurs in a manner that is dependent on the E3 ligase activity of TRAF6 its ability to
dimerize (Figure S7). It will thus be interesting to study the functional consequences of
TRAF6-mediated IKKε ubiquitination in the future.
5. Conclusions
This work identifies IKKε-mediated TRAF6 phosphorylation as a novel mechanism
that controls TRAF6 stability and signal output. Phosphorylated TRAF6 is largely pro-
tected from basal ubiquitin/proteasome-mediated degradation and also from autophagy-
mediated decay, thus providing another example that shows the cross-regulation between
metabolic and inflammatory circuits. The metabolic regulation of TRAF6 stability and its
implications for downstream signaling can probably also contribute to smoldering inflam-
mation that is associated with aging and metabolic diseases such as diabetes and obesity.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13143618/s1, Figure S1: MS2 Spectra of TRAF6 phosphorylation sites only seen in
presence of IKKε, Figure S2: (A) 293 TLR4 cells were transfected with the vector px459-TRAF6 which
directs the synthesis of Cas9 and a sgRNA targeting the first exon of TRAF6. Transfected cells were
selected by puromycin treatment and surviving clones were grown to colonies. A fraction of the
indicated cell clones was lysed and equal amounts of protein were tested by immunoblotting for
expression levels of TRAF6, Cas9 and Tubulin with specific antibodies. (B) TRAF6-deficient cells
Cancers 2021, 13, 3618 17 of 20
were tested for the occurrence of genetic changes by PCR and sequencing. The underlined areas
were deleted and the G was inserted as shown, leading to frame-shifts and defect TRAF6 expression,
Figure S3: HeLa cells were exposed for the indicated periods to EBSS medium and analyzed by
Western blotting for expression of the indicated proteins, Figure S4: The indicated cell lines were
incubated with EBSS medium for 5 h as shown and simultaneously treated with increasing amounts
of the proteasome inhibitor Lactacystin (5, 10 µM), Figure S5: The Venn diagrams show the number of
phosphopeptides measured under the indicated conditions in the various cells. The numbers in the
brackets indicate (all P-peptides; unique P-peptides), Figure S6: Protein Ids mapping to the unique
groups of deregulated phosphopeptides shown were further used to perform an overrepresentation
(ORA) analysis using Metascape, Figure S7: HEK293 cells expressing Flag-IKKε alone or along with
His6-ubiquitin and the indicated TRAF6 variants (C70A: defective in E3 ligase function; K124R:
defective in autoubiquitination; R88A and R88A/F122A: defective in dimerization) were lysed
under denaturing conditions, Figure S8: Whole Western Blots, Table S1: Antibodies and plasmids,
Table S2: Phosphoproteomic analysis. References [63–66] are referred to in Supplementary Materials.
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